Amylyx Pharmaceuticals Valuation
| AMLX Etf | USD 5.54 0.20 3.48% |
At this time, the entity appears to be undervalued. Amylyx Pharmaceuticals shows a prevailing Real Value of $10.75 per share. The current price of the entity is $5.54. Our model approximates the value of Amylyx Pharmaceuticals from analyzing the entity fundamentals such as Current Valuation of 147.93 M, profit margin of (1.32) %, and Return On Equity of -0.84 as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.9355 | Enterprise Value 147.9 M | Enterprise Value Ebitda (11.71) | Price Sales 2.0025 | Forward PE 2.7739 |
Undervalued
Today
Please note that Amylyx Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Amylyx Pharmaceuticals is based on 3 months time horizon. Increasing Amylyx Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Amylyx Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amylyx Etf. However, Amylyx Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.54 | Real 10.75 | Target 47.6 | Hype 5.77 | Naive 5.8 |
The intrinsic value of Amylyx Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Amylyx Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Amylyx Pharmaceuticals helps investors to forecast how Amylyx etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amylyx Pharmaceuticals more accurately as focusing exclusively on Amylyx Pharmaceuticals' fundamentals will not take into account other important factors: Amylyx Pharmaceuticals Total Value Analysis
Amylyx Pharmaceuticals is presently expected to have valuation of 147.93 M with market capitalization of 393.46 M, debt of 4.24 M, and cash on hands of 206.68 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Amylyx Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
147.93 M | 393.46 M | 4.24 M | 206.68 M |
Amylyx Pharmaceuticals Investor Information
Based on the key indicators related to Amylyx Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Amylyx Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Amylyx Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Amylyx Pharmaceuticals has an asset utilization ratio of 73.59 percent. This suggests that the ETF is making $0.74 for each dollar of assets. An increasing asset utilization means that Amylyx Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Amylyx Pharmaceuticals Ownership Allocation
Amylyx Pharmaceuticals holds a total of 68.55 Million outstanding shares. The majority of Amylyx Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amylyx Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amylyx Pharmaceuticals. Please pay attention to any change in the institutional holdings of Amylyx Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.Amylyx Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 380.79 M. Net Income was 49.27 M with loss before overhead, payroll, taxes, and interest of (74.21 M).About Amylyx Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Amylyx Pharmaceuticals. We calculate exposure to Amylyx Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Amylyx Pharmaceuticals's related companies.Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.
Amylyx Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 70 M | |
| Forward Price Earnings | 2.7739 |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.